Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Eyepoint Pharmaceuticals stock

Learn how to easily invest in Eyepoint Pharmaceuticals stock.

Eyepoint Pharmaceuticals Inc is a biotechnology business based in the US. Eyepoint Pharmaceuticals shares (EYPT) are listed on the NASDAQ and all prices are listed in US Dollars. Eyepoint Pharmaceuticals employs 122 staff and has a trailing 12-month revenue of around $41.5 million.

How to buy shares in Eyepoint Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EYPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Eyepoint Pharmaceuticals stock price (NASDAQ: EYPT)

Use our graph to track the performance of EYPT stocks over time.

Eyepoint Pharmaceuticals shares at a glance

Information last updated 2022-09-20.
Latest market close$7.20
52-week range$7.00 - $21.50
50-day moving average $9.77
200-day moving average $10.62
Wall St. target price$33.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.11

Buy Eyepoint Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Eyepoint Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eyepoint Pharmaceuticals price performance over time

Historical closes compared with the close of $7.2 from 2022-09-23

1 week (2022-09-19) -7.46%
1 month (2022-08-26) -29.96%
3 months (2022-06-24) -0.69%
6 months (2022-03-25) -43.31%
1 year (2021-09-24) -38.57%
2 years (2020-09-25) 1,177.28%
3 years (2019-09-26) 300.00%
5 years (2017-09-26) 480.65%

Eyepoint Pharmaceuticals financials

Revenue TTM $41.5 million
Gross profit TTM $262,000
Return on assets TTM -21.49%
Return on equity TTM -59.26%
Profit margin -184.53%
Book value $4.45
Market capitalisation $265.1 million

TTM: trailing 12 months

Eyepoint Pharmaceuticals share dividends

We're not expecting Eyepoint Pharmaceuticals to pay a dividend over the next 12 months.

Have Eyepoint Pharmaceuticals's shares ever split?

Eyepoint Pharmaceuticals's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eyepoint Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Eyepoint Pharmaceuticals shares which in turn could have impacted Eyepoint Pharmaceuticals's share price.

Eyepoint Pharmaceuticals share price volatility

Over the last 12 months, Eyepoint Pharmaceuticals's shares have ranged in value from as little as $6.995 up to $21.5. A popular way to gauge a stock's volatility is its "beta".

EYPT.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyepoint Pharmaceuticals's is 1.2141. This would suggest that Eyepoint Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Eyepoint Pharmaceuticals overview

EyePoint Pharmaceuticals, Inc. , a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc. , Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc.

Frequently asked questions

What percentage of Eyepoint Pharmaceuticals is owned by insiders or institutions?
Currently 11.705% of Eyepoint Pharmaceuticals shares are held by insiders and 89.426% by institutions.
How many people work for Eyepoint Pharmaceuticals?
Latest data suggests 122 work at Eyepoint Pharmaceuticals.
When does the fiscal year end for Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals's fiscal year ends in December.
Where is Eyepoint Pharmaceuticals based?
Eyepoint Pharmaceuticals's address is: 480 Pleasant Street, Watertown, MA, United States, 02472
What is Eyepoint Pharmaceuticals's ISIN number?
Eyepoint Pharmaceuticals's international securities identification number is: US30233G2093
What is Eyepoint Pharmaceuticals's CUSIP number?
Eyepoint Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 30233G100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site